View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
February 22, 2021

Luminex receives BARDA funding to develop SARS-CoV-2 test

The US Biomedical Advanced Research and Development Authority (BARDA) has awarded Luminex funding worth $11.3m for developing and validating a respiratory panel, combining flu A/B and respiratory syncytial virus (RSV) targets with the SARS-CoV-2 target that can be run on all ARIES Systems.

The US Biomedical Advanced Research and Development Authority (BARDA) has awarded Luminex funding worth $11.3m for developing and validating a respiratory panel, combining flu A/B and respiratory syncytial virus (RSV) targets with the SARS-CoV-2 target that can be run on all ARIES Systems.

Free Report
img

What’s missing from your IPO industry assessment?

IPO activity all but stopped in 2020, as the investment community grew wary of the effects of COVID-19 on economies. No matter how deserving a business was of flotation, momentum was halted by concerns of when a ‘new normal’ of working patterns and trade would set in. Recently, sentiment has changed. Flotations picked up again during the second half of 2021, and now in 2022 the mood is decidedly optimistic. Business leaders have their eyes on fast rebounding economies, buoyant market indices and the opportunity once again to take their businesses public. As a result, global IPOs are expected to hit back this year. With GlobalData’s new whitepaper, ‘IPOs in Consumer and Retail: 5 must-include elements for your prospectus industry report’, you can explore exactly what is needed in the essential literature. GlobalData’s focus lies in the critical areas to get right:
  • Macroeconomic and demographic environment
  • Consumer context
  • Industry environment
  • Competitive environment
  • Route to market
Interested to learn more about what to include in your IPO Industry Assessment report? Download our free whitepaper.
by GlobalData
Enter your details here to receive your free Report.

The six and 12-cassette systems are automated molecular diagnostic platforms used in moderate and high-complexity labs with various tests that received clearance from the US F ood and Drug Administration (F DA).

They can deliver results in under two hours with the minimum hands-on time needed.

Currently, clinical labs, which are challenged by continued Covid-19 testing, are under extra pressure to meet the testing demand linked to seasonal flu and RSV at the same time.

As the symptoms of flu and RSV are similar to Covid-19, it becomes difficult for physicians to differentiate between them.

A single test that could identify these pathogens simultaneously will help labs to receive more complete test results rapidly without needing additional reagents and other consumables, the company said.

Luminex chairman, president, and CEO Nachum ‘Homi’ Shamir said: “We believe that this targeted multiplex assay will play a pivotal role in helping healthcare professionals efficiently and effectively manage individuals with respiratory illness symptoms for years to come.

“We are grateful to BARDA for its continued support as we seek to streamline respiratory testing with a single assay for the most common pathogens.

“This will allow laboratories, most of which are already operating in resource-constrained environments, to run one test instead of two or more without sacrificing clinical results.”

The company developed the original ARIES SARS-CoV-2 (EUA) assay with financial aid from BARDA last year.

It noted that the ARIES F lu A/B & RSV+SARS-CoV-2 Assay could identify influenza A/B, RSV, and SARS-CoV-2 simultaneously in a single test, support advanced testing, and reduce supply pressures.

Luminex intends to seek emergency use authorisation (EUA) for the targeted multiplex respiratory panel from the F DA soon and also plans to submit it for 510(k) clearance.

Last March, Luminex received the F DA’s EUA for its NxTAG CoV Extended Panel test intended to detect the SARS-CoV-2 virus that causes Covid-19.

Related Companies

Free Report
img

What’s missing from your IPO industry assessment?

IPO activity all but stopped in 2020, as the investment community grew wary of the effects of COVID-19 on economies. No matter how deserving a business was of flotation, momentum was halted by concerns of when a ‘new normal’ of working patterns and trade would set in. Recently, sentiment has changed. Flotations picked up again during the second half of 2021, and now in 2022 the mood is decidedly optimistic. Business leaders have their eyes on fast rebounding economies, buoyant market indices and the opportunity once again to take their businesses public. As a result, global IPOs are expected to hit back this year. With GlobalData’s new whitepaper, ‘IPOs in Consumer and Retail: 5 must-include elements for your prospectus industry report’, you can explore exactly what is needed in the essential literature. GlobalData’s focus lies in the critical areas to get right:
  • Macroeconomic and demographic environment
  • Consumer context
  • Industry environment
  • Competitive environment
  • Route to market
Interested to learn more about what to include in your IPO Industry Assessment report? Download our free whitepaper.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Medical Device Network